SEARCH

SEARCH BY CITATION

References

  • 1
    Saklatvala J: Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322: 547549, 1986
  • 2
    Bertolini DR, Nedwin GE, Bringman TS, Smith DE, Mundy GR: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factor. Nature 319: 516518, 1986
  • 3
    Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA: Stimulation of the adherence of neutrophils to umbilical endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A 82: 86678671, 1985
  • 4
    Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkle BS, Palladino MA: Activation of human polymorphonuclear neutrophil function by interferon gamma and tumor necrosis factor. J Immunol 135: 20692073, 1985
  • 5
    Collins T, Lapierre LA, Fiers W, Strominger JL, Pober JS: Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci U S A 83: 446450, 1986
  • 6
    Vilček J, Palombella VJ, Henriksen-De Stefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M: Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163: 632643, 1986
  • 7
    Dayer J-M, Beutler B, Cerami A: Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 21632168, 1985
  • 8
    Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M: Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet II: 244247, 1989
  • 9
    Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granulocyte-macro-phage colony stimulating factor (GM-CSF) in rheumatoid arthritis: regulation by tumour necrosis factor α. Eur J Immunol 21: 25752579, 1991
  • 10
    Williams RO, Feldmann M, Maini RF: Anti-tumour necrosis factor treatment inhibits the progression of established collagen-induced arthritis (abstract). Arthritis Rheum 34(suppl 9): S67, 1991
  • 11
    Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Katsikis P, Londei M, Abney E, Buchan G, Barrett K, Corcoran A, Kissonerghis M, Zheng R, Grubeck-Loebenstein B, Barkley D, Chu CQ, Field M, Maini RN: Cytokine assays: role in evaluation of the pathogenesis of autoimmunity. Immunol Rev 119: 105123, 1991
  • 12
    Gray PW, Barrett K, Chantry D, Turner M, Feldmann M: Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc Natl Acad Sci U S A 87: 73807384, 1990
  • 13
    Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GHW, Gatanaga T, Granger GA, Lentz R, Raab H, Kohr WJ, Goeddel DV: Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61: 361370, 1990
  • 14
    Nophar Y, Kemper O, Brakebusch C, Engelmann H, Zwang R, Aderka D, Holtmann H, Wallach D: Soluble forms of tumour necrosis factor receptors (TNF-Rs): the cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9: 32693278, 1990
  • 15
    Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RG: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248: 10191023, 1990
  • 16
    Heller RA, Song K, Onasch MA, Fischer WH, Chang D, Ringold GM: Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor. Proc Natl Acad Sci U S A 87: 61516155, 1990
  • 17
    Kohno T, Brewer MT, Baker SL, Schwartz PE, King MW, Hale KK, Squires CH, Thompson RC, Vannice JL: A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci U S A 87: 83318335, 1990
  • 18
    Novick D, Engelmann H, Wallach D, Rubenstein M: Soluble cytokine receptors are present in normal urine. J Exp Med 170: 14091414, 1989
  • 19
    Engelmann H, Novick D, Wallach D: Two tumor necrosis factor-binding proteins purified from human urine. J Biol Chem 265: 15311536, 1990
  • 20
    Seckinger P, Isaaz S, Dayer J-M: A human inhibitor of TNFα. J Exp Med 167: 15111516, 1988
  • 21
    Olsson I, Lantz M, Nilsson E: Isolation and characterisation of a tumour necrosis factor binding protein from urine. Eur J Haematol 42: 270275, 1989
  • 22
    Seckinger P, Isaaz S, Dayer J-M: Purification and biologic characterization of a specific tumor necrosis factor inhibitor. J Biol Chem 264: 1196611973 1989
  • 23
    Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51: 56025607, 1991
  • 24
    Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M: Enhanced expression of TNF receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 22: 19071912, 1992
  • 25
    Deleuran BD, Chu C-Q, Field M, Brennan FM, Mitchell T, Feldmann M, Maini RN: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage–pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 35: 11701178, 1992
  • 26
    Keystone EC, Snow KM, Bombardier C, Chang C-H, Nelson DL, Rubin LA: Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum 31: 844849, 1988
  • 27
    Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9: 175176, 1958
  • 28
    Doherty M, Richards N, Hornby J, Powell R: Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy. Ann Rheum Dis 47: 190197, 1988
  • 29
    Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343: 336340, 1990
  • 30
    Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL: Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 31723177, 1985
  • 31
    Fernandez-Botran R, Vitetta ES: A soluble, high affinity interleukin-4 binding protein is present in the biological fluids of mice. Proc Natl Acad Sci U S A 87: 42024206, 1990
  • 32
    Tavernier J, Devos R, Cornelis S, Tuypens T, van der Heyden J, Fiers W, Plaetinck G: A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific α chain and a β chain shared with the receptor for GM-CSF. Cell 66: 11751184, 1991
  • 33
    Goodwin RG, Friend D, Ziegler SF, Jerzy R, Falk BA, Gimpel S, Cosman D, Dower SK, March CJ, Namen AE, Park LS: Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 60: 941951, 1990
  • 34
    Downing JR, Roussel MF, Sherr CJ: Protein kinase C “transmodulates” the colony stimulating factor-1 receptor by activating a membrane-associated protease that specifically releases the receptor ligand-binding domain from the cell. Clin Res 37: 544A, 1989
  • 35
    Feldmann M: Review: cytokine networks; do we understand them well enough to facilitate clinincal benefits? Eur Cytokine Net 2: 59, 1991
  • 36
    Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M: Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-lα. Clin Exp Immunol 73: 449455, 1988
  • 37
    Aderka D, Engelmann H, Wyssenbeek, Cope AP, Molad Y, Feldmann M, Hornick V, Maini RN, Alpert G, Levo Y, Wallach D: Increased serum soluble receptors for tumour necrosis factor in systemic lupus erythematosus correlate with disease activity. Submitted for publication
  • 38
    Robb RJ, Kutny RM: Structure-function relationships for the IL-2 receptor system IV analysis of the sequence and ligand binding properties of soluble Tac protein. J Immunol 139: 855862, 1987
  • 39
    Andrews JS, Berger AE, Ware CF: Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. J Immunol 144: 25822591, 1990
  • 40
    Brockhaus M, Schoenfeld HJ, Schlaeger E-J, Hunziker W, Lesslauer W, Loetscher H: Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 87: 31273131, 1990
  • 41
    Porteu F, Nathan C: Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172: 599607, 1990
  • 42
    Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan C: Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. J Biol Chem 266: 1884618853, 1991
  • 43
    Symons JA, Wood NC, Di Giovane FS, Duff GW: Soluble IL-2 receptor in rheumatoid arthritis: correlation with disease activity, IL-1, and IL-2 inhibition. J Immunol 141: 26122618, 1988